Spike Protein News and Research

RSS

Do mRNA-based COVID-19 vaccines induce memory T cell response similar to natural infection?

A team of scientists from the United States has recently compared the epitope-specific T cell response after natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or vaccination in both naïve and previously infected individuals.

19 Jul 2021

Researchers conduct molecular dynamic study of SARS-CoV-2 spike glycoprotein and human skin model interactions

Currently, there is a lack of understanding of the physico-chemical features of the interaction between coronaviruses and different surfaces. However, new research has been published on the bioRxiv* preprint server that documents the molecular details of the interaction between the human skin and SARS-CoV-2.

19 Jul 2021

Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection

Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall responses to future infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Jul 2021

How do immunocompromised patients respond to COVID-19 vaccines?

The COVID-19 vaccines produce a boost in antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, new research suggests vaccine responses aren’t all created equal. Their findings showed that immunocompromised patients, such as transplant recipients, with no prior exposure to SARS-CoV-2 produce little to no neutralizing antibodies.

18 Jul 2021

Mixing COVID vaccines generates a comparable immune response

The validity and safety of mixing first and second doses of different types are explored in a paper recently uploaded to the preprint server medRxiv* by Rose et al. (July 13th, 2021), finding that robust antibody response is induced, comparable to, and perhaps even exceed that generated by homologous dosing.

16 Jul 2021

COVID-19 vaccine candidate that can be produced in yeast proves effective in macaques

Researchers in the United States have designed a modular protein subunit vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that elicited a strong immune response in macaques and prevented the animals from developing coronavirus disease 2019 (COVID-19).

15 Jul 2021

A rapid, highly accurate test to detect antibodies against SARS-CoV-2 in human serum

Scientists have developed a rapid, highly accurate test to detect antibodies against the spike protein of SARS-CoV-2 in human serum, opening a new avenue for understanding the full extent of the pandemic and evaluating the effectiveness of vaccines.

15 Jul 2021

Should we be concerned about the SARS-CoV-2 Lambda variant?

As the coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wreaks havoc across the globe, the efficacy of available vaccines is being threatened by emerging variants.

15 Jul 2021

New OMV-based COVID-19 vaccine candidate proves effective in mice

Researchers in Italy have demonstrated the efficacy of using modified outer membrane vesicles (OMVs) as a vaccine to protect against coronavirus disease 2019 (COVID-19) in an animal model.

14 Jul 2021

Researchers examine efficacy of CT-P59 monoclonal antibody against SARS-CoV-2 Brazil variant

The therapeutic monoclonal antibody CT-P59 binds to the RBD of SARS-CoV-2, the site of these three major mutations, which may therefore reduce the potency of this antibody against the P.1 lineage. In a new study, the neutralizing potency of this monoclonal antibody towards both wildtype and P.1 SARS-CoV-2 is investigated. The researchers found that the ability to bind with the virus is impeded by the mutations, resulting in reduced potency in vitro.

14 Jul 2021

SARS-CoV-2 variants show distinct humoral response and transcriptional profiles in hamster model

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel, highly infectious respiratory virus, and the causative agent of coronavirus disease 2019 (COVID-19) pandemic. SARS-CoV-2, which first originated in Wuhan, in Hubei province of China, is a member of the Coronavirdae family and has a large, non-segmented RNA genome.

14 Jul 2021

SARS-CoV-2 mutations occur in essentially the same locations, research finds

New research from the University of Nebraska-Lincoln has shown that the mutations arising in the COVID-19-causing SARS-CoV-2 virus seem to run in the family -- or at least the genus of coronaviruses most dangerous to humans.

14 Jul 2021

Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets

Researchers in the United States have demonstrated that the viral spike protein used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells adopts an open conformation exposing novel epitopes that could serve as targets for therapeutic strategies to protect against coronavirus disease 2019 (COVID-19).

14 Jul 2021

Scientists develop mouse-specific SARS-CoV-2 strains that efficiently replicate in standard laboratory mice

A team of scientists in France recently developed a mouse-adapted strain of SARS-CoV-2 that efficiently replicates in the lungs of standard laboratory mice and induces mild to moderate disease. The study is currently available on the bioRxiv* preprint server.

13 Jul 2021

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

A recent study published in the MDPI journal, Pathogens, describes a coronavirus peptide vaccine antigen in the form of nanodiamond-based formulations, that demonstrated a robust and long-lasting immune response. The nanodiamonds proved to be a powerful and versatile platform for antigen conjugation. This could make it a safe and effective strategy for the production of off-the-shelf vaccines against multiple coronaviruses.

13 Jul 2021

Review details clinical signs of SARS-CoV-2 infection in domestic and wild cats

Now, a new systematic review has been published in the journal Animals that focuses on the clinical symptoms in felines diagnosed with SARS-CoV-2 worldwide.

13 Jul 2021

Natural compound 'pheophorbide a' demonstrates robust antiviral activity against SARS-CoV-2 in vitro

A team of scientists from France has recently demonstrated photosensitive antiviral activity of the natural compound pheophorbide a (Pba) against a broad range of enveloped viruses, including coronaviruses.

12 Jul 2021

New research examines the elimination of the B.1.362 + L452R variant in Israel

Is it possible to completely get rid of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants? New research led by Neta S. Zuckerman of Sheba Medical Center in Israel suggests it’s possible. Their report details the upsurge of a B.1.362 variant harboring the L452R mutation that eventually disappeared due to vaccination efforts and the presence of more robust variants.

12 Jul 2021

Scientists identify novel entry receptors for SARS-CoV-2

Scientists from the Northeastern University, China, and University of Michigan, USA, have recently identified five potential entry receptors for SARS-CoV-2. These receptors specifically express in SARS-CoV-2-infected cells and have a high binding affinity for the viral spike protein.

12 Jul 2021

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Scientists from the US and Germany have recently evaluated the efficacy of an mRNA-based COVID-19 vaccine candidate, CV07050101, in inducing humoral and cellular immune responses in non-human primates. The study reveals that prime-boost immunization with the vaccine candidate induces only limited immunity against SARS-CoV-2.

12 Jul 2021

Spike Protein News and Research

Do mRNA-based COVID-19 vaccines induce memory T cell response similar to natural infection?

Researchers conduct molecular dynamic study of SARS-CoV-2 spike glycoprotein and human skin model interactions

Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection

How do immunocompromised patients respond to COVID-19 vaccines?

Mixing COVID vaccines generates a comparable immune response

COVID-19 vaccine candidate that can be produced in yeast proves effective in macaques

A rapid, highly accurate test to detect antibodies against SARS-CoV-2 in human serum

Should we be concerned about the SARS-CoV-2 Lambda variant?

New OMV-based COVID-19 vaccine candidate proves effective in mice

Researchers examine efficacy of CT-P59 monoclonal antibody against SARS-CoV-2 Brazil variant

SARS-CoV-2 variants show distinct humoral response and transcriptional profiles in hamster model

SARS-CoV-2 mutations occur in essentially the same locations, research finds

Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets

Scientists develop mouse-specific SARS-CoV-2 strains that efficiently replicate in standard laboratory mice

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

Review details clinical signs of SARS-CoV-2 infection in domestic and wild cats

Natural compound 'pheophorbide a' demonstrates robust antiviral activity against SARS-CoV-2 in vitro

New research examines the elimination of the B.1.362 + L452R variant in Israel

Scientists identify novel entry receptors for SARS-CoV-2

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News